The examination of the effects of Teneligliptin on blood glucose and albuminuria in type 2 diabetic patients with nephropathy, whose glycemic control is insufficient.

Trial Profile

The examination of the effects of Teneligliptin on blood glucose and albuminuria in type 2 diabetic patients with nephropathy, whose glycemic control is insufficient.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Jun 2017

At a glance

  • Drugs Teneligliptin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Jun 2017 Planned End Date changed from 31 Dec 2016 to 20 Sep 2017.
    • 27 Dec 2016 Status changed from recruiting to active, no longer recruiting.
    • 16 Dec 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top